H5N1 avian influenza vaccine intranasal - MedImmune/NIAID

Drug Profile

H5N1 avian influenza vaccine intranasal - MedImmune/NIAID

Alternative Names: Avian flu vaccine - MedImmune/NIAID; H5N1 influenza vaccine - MedImmune/NIAID; MEDI-550; MEDI-566; Pandemic influenza vaccine - MedImmune/NIAID

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MedImmune Vaccines; National Institute of Allergy and Infectious Diseases
  • Developer MedImmune Vaccines
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Influenza A virus H5N1 subtype

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(Prevention) in USA (Intranasal)
  • 01 Apr 2016 The Committee for Medicinal Products for Human Use recommends approval of Influenza-A virus H5N1 subtype vaccine for Influenza-A virus H5N1 subtype (Prevention) in European Union (Intranasal)
  • 31 Dec 2015 Preregistration for Influenza-A virus H5N1 subtype(Prevention) in European Union (Intranasal) (AstraZeneca's pipeline, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top